Core Viewpoint - Clear Medical (01406) reported a revenue of approximately HKD 85 million for the first half of the fiscal year ending 2026, reflecting a slight decline of less than 3% compared to the same period last year due to adverse weather conditions and negative media coverage [1] Financial Performance - The company achieved revenues of about HKD 85 million, which is a minor decrease of less than 3% year-on-year [1] - The Hong Kong clinics experienced operational disruptions for eight days from July to September due to extreme weather conditions [1] Business Developments - The company has strengthened its technological leadership in the Hong Kong ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce the new generation refractive surgery technology SILK™ [1] - SILK™ technology utilizes low-energy, ultra-precise femtosecond laser pulses to minimize corneal and nerve tissue damage, leading to faster recovery and improved postoperative outcomes [1] - Clear Medical plans to promote the SILK™ technology in the fourth quarter of 2025, being the first and only institution in Hong Kong to offer this technology [1]
清晰医疗(01406)2026财年半年度实现收益约8500万港元 同比下降不足3%